NRGN and Alzheimer disease: One trial, COG0102 (NCT02907567), reported that in CT1812-treated AD patients, neurogranin (Nrgn) and synaptotagmin-1 (Syt1), which are proteins associated with synaptic damage, were decreased in CSF, suggesting that CT1812 may play a role in improving synaptic function and preservation [10].